Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goserelin plus Fulvestrant vs Anastrozole in Advanced Breast Cancer
NCT02072512Phase 2Unknown
- Sponsor
- 307 Hospital of the People's Liberation Army
- Start
- Jan 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant in breast cancer (2 arms), sponsored by 307 Hospital of the People's Liberation Army. Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02072512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072512.